Agilent Technologies (NYSE:A) posted its quarterly earnings data on Thursday. The medical research company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.10, MarketWatch Earnings reports. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.20 billion. Agilent Technologies had a return on equity of 20.75% and a net margin of 13.04%. The firm’s revenue for the quarter was up .2% on a year-over-year basis. During the same period last year, the firm earned $0.71 EPS.
NYSE:A opened at $84.98 on Friday. Agilent Technologies has a 52-week low of $61.13 and a 52-week high of $90.64. The company has a quick ratio of 1.27, a current ratio of 1.64 and a debt-to-equity ratio of 0.37. The stock has a fifty day simple moving average of $77.33 and a 200-day simple moving average of $79.96. The company has a market capitalization of $25.00 billion, a PE ratio of 25.47 and a beta of 1.10.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 22nd. Stockholders of record on Tuesday, June 30th will be given a $0.18 dividend. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date is Monday, June 29th. Agilent Technologies’s dividend payout ratio is currently 23.15%.
A number of equities analysts recently weighed in on the stock. Wells Fargo & Co lifted their price objective on shares of Agilent Technologies from $82.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday. Stifel Nicolaus lowered their target price on shares of Agilent Technologies from $85.00 to $73.00 and set a “hold” rating on the stock in a report on Thursday, April 2nd. Bank of America boosted their price target on shares of Agilent Technologies from $74.00 to $88.00 and gave the stock a “neutral” rating in a research note on Friday. Needham & Company LLC downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating and set a $85.00 price objective for the company. in a research report on Monday, February 24th. Finally, UBS Group lifted their price objective on Agilent Technologies from $84.00 to $87.00 and gave the company a “neutral” rating in a report on Friday. Eleven equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $85.75.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Featured Story: Liquidity
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.